Cargando…

Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis

BACKGROUND: Members of the urokinase-type plasminogen activator (uPA) system including uPA, its receptor uPAR and the plasminogen activator inhibitor 1 (PAI-1) play an important role in tumour invasion and progression in a variety of tumour types. Since the majority of clear cell renal cell carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuessel, Susanne, Erdmann, Kati, Taubert, Helge, Lohse-Fischer, Andrea, Zastrow, Stefan, Meinhardt, Matthias, Bluemke, Karen, Hofbauer, Lorenz, Fornara, Paolo, Wullich, Bernd, Baretton, Gustavo, Magdolen, Viktor, Wirth, Manfred P, Kotzsch, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301943/ https://www.ncbi.nlm.nih.gov/pubmed/25519168 http://dx.doi.org/10.1186/1471-2407-14-974

Ejemplares similares

Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer
por: Al-Janabi, Omar, et al.
Publicado: (2014)

Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients
por: Kotzsch, Matthias, et al.
Publicado: (2011)

Lack of Ephrin Receptor A1 Is a Favorable Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
por: Toma, Marieta I., et al.
Publicado: (2014)

Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma
por: Weber, Thomas, et al.
Publicado: (2014)

Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients
por: Taubert, H, et al.
Publicado: (2010)

Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma
por: Dornbusch, Juana, et al.
Publicado: (2013)

Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions
por: Keck, Bastian, et al.
Publicado: (2021)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells
por: Hahnel, Antje, et al.
Publicado: (2010)

Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells
por: Grismayer, Bettina, et al.
Publicado: (2012)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
por: Lee, Ji-Hye, et al.
Publicado: (2014)

The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type
Publicado: (1986)

Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD
por: Sommerer, Claudia, et al.
Publicado: (2023)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
por: Spinale, Joann M., et al.
Publicado: (2014)

High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients
por: Rachner, Tilman D, et al.
Publicado: (2014)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts
por: Chao, Shih-Chun, et al.
Publicado: (2011)

Urokinase-type plasminogen activator receptor in IgA nephropathy
por: Ahn, Shin-Young, et al.
Publicado: (2014)

Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
por: Ierodiakonou, Despo, et al.
Publicado: (2016)

Urokinase-type Plasminogen Activator Induces Neurorepair in the Ischemic Brain
por: Merino, Paola, et al.
Publicado: (2018)

Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and α2-antiplasmin in human corneal perforation: a case report
por: Sugioka, Koji, et al.
Publicado: (2012)

Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA
por: Dreymann, Nico, et al.
Publicado: (2022)

The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review
por: Tucker, Torry A., et al.
Publicado: (2021)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Enhanced Inhibition of Bladder Cancer Cell Growth by Simultaneous Knockdown of Antiapoptotic Bcl-xL and Survivin in Combination with Chemotherapy
por: Kunze, Doreen, et al.
Publicado: (2013)

Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation
por: Erdmann, Kati, et al.
Publicado: (2017)

Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients
por: Hahnel, Antje, et al.
Publicado: (2012)

Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
por: Cantero, D., et al.
Publicado: (1997)

Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells
Publicado: (1987)

immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma
por: Skriver, L, et al.
Publicado: (1984)

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014)

Urokinase-type plasminogen activator: a new target for male contraception?
por: Qin, Ying, et al.
Publicado: (2015)

Urokinase-Type Plasminogen Activator Deficiency Promotes Neoplasmatogenesis in the Colon of Mice()()()
por: Karamanavi, Elisavet, et al.
Publicado: (2014)

Urokinase-type plasminogen activator promotes synaptic repair in the ischemic brain
por: Diaz, Ariel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eublcsrut9jnstnnoc4ph4ng01